Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Akero Therapeutics Inc AKRO

Healthcare Biotechnology
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing... see more

Recent & Breaking News (NDAQ:AKRO)

Akero Therapeutics Appoints Yuan Xu to its Board of Directors

GlobeNewswire April 26, 2021

Akero Therapeutics Announces First Patient Randomized for Dosing in Phase 2b Study of Efruxifermin (EFX) in F2/F3 NASH Patients (HARMONY)

GlobeNewswire March 23, 2021

Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C

GlobeNewswire March 22, 2021

Akero Therapeutics to Announce New Data from an Evaluation of Efruxifermin (EFX) in Cirrhotic NASH (F4) Patients

GlobeNewswire March 22, 2021

Akero Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

GlobeNewswire March 16, 2021

Akero Therapeutics to Participate in Upcoming Virtual Healthcare Conferences in March

PR Newswire February 23, 2021

Akero Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Business Wire January 4, 2021

Akero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference

Business Wire November 24, 2020

Akero Presents Additional Positive Data from Phase 2a BALANCED Study Demonstrating Potential of Efruxifermin as a Foundational NASH Monotherapy

Business Wire November 13, 2020

Akero Therapeutics Reports Third Quarter 2020 Financial Results

PR Newswire November 12, 2020

Akero Therapeutics To Present At Upcoming Conferences In November

PR Newswire October 21, 2020

Akero Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for Efruxifermin (EFX) in NASH

PR Newswire October 16, 2020

Akero Therapeutics To Present Data From Phase 2a BALANCED Study Of Efruxifermin In NASH Patients In Presidential Plenary Talk At The Liver Meeting® 2020

PR Newswire October 2, 2020

Akero Therapeutics Completes Enrollment of Cohort of Cirrhotic (F4) Patients In Ongoing Balanced Study

PR Newswire September 30, 2020

Akero Therapeutics to Present at H.C. Wainwright's 4th Annual NASH Virtual Investor Conference

PR Newswire September 28, 2020

Akero Therapeutics To Continue Efruxifermin Development With Innovative Adaptive Phase 2b/3 Clinical Trial Design Based On FDA Written Guidance

PR Newswire September 24, 2020

Akero Therapeutics To Present At Morgan Stanley's 18th Annual Global Healthcare Conference

PR Newswire September 9, 2020

Akero Therapeutics Reports Second Quarter 2020 Financial Results

PR Newswire August 12, 2020

Research Published in Cell Reports Medicine Highlights Potential of Akero Therapeutics' NASH Therapeutic Candidate

PR Newswire July 21, 2020

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

PR Newswire July 10, 2020